AI Drug Discovery for Pharma and Biotech

Drug discovery

143

drugs

With orphan designations

Overview

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease characterized by irreversible lung scarring (usual interstitial pneumonia pattern) and declining lung function [1][6]. Median survival is 2–5 years post-diagnosis, with respiratory failure as the primary cause of death [6][16]. Diagnosis requires exclusion of secondary causes and confirmation via HRCT or histopathology [6][16].

Population

  • Primarily affects adults >50 years (mean age 65–70), with incidence rising sharply after age 55 (19.3/100,000 person-years in 55–64 year-olds) [2][17]

  • Male predominance (incidence ratio 1.08 male:female) [2][7]

  • Estimated US prevalence: 42.7–63/100,000 [4][12]

Burden

  • Median survival 2–5 years; comparable to aggressive cancers [6][16]

  • Annual US healthcare costs ~$20,000/patient (2.5–3.5× national average) [4]

  • 61.7/100 mean EQ-5D QoL score, with 24–64% annual hospitalization rates [9][11]

Therapies

  • Antifibrotics (pirfenidone, nintedanib) to slow progression (30% reduction in FVC decline) [5][13]

  • Supportive care: oxygen therapy, pulmonary rehabilitation, symptom management [1][5]

  • Lung transplantation (only curative option; 1,400+ performed at leading centers) [1][6]

Categories: rare respiratory diseases, rare transplant-related disorders

Research Papers

6,425 drug discovery papers about Idiopathic pulmonary fibrosis, with 2 first-in-class and 117 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

6,425 drug discovery papers about Idiopathic pulmonary fibrosis, with 2 first-in-class and 117 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

2026-08-13 | The telomeric DNA damage response as a therapeutic target in idiopathic pulmonary fibrosis.

Telomere dysfunction and the telomeric DNA damage response (tDDR) activation correlate with aging and age-related diseases, including idiopathic pulmonary fibrosis (IPF). However, a causal role for tDDR in IPF pathogenesis has not been determined. IPF patients frequently bear germline mutations in telomerase genes, critically short telomeres, and markers of tDDR and cellular senescence. We previously demonstrated that telomeric antisense-oligonucleotides (tASOs) targeting telomeric non-coding RNAs are selective tDDR inhibitors. Here, we employed late-generation telomerase knockout mice as a genetic model of IPF. Systemic tASOs treatment reduces DDR-including in stem/progenitor cells-inflammation, and lung fibrosis in young, adult, and old mice. Markers of DDR correlate with lung pathology, and tDDR inhibition normalizes molecular and pathological phenotypes, uncoupling telomere lengths from their deleterious consequences. Transcriptomic changes in telomerase knockout mice recapitulate those observed in normal aged mice and in IPF patients, and they are reversed upon tDDR inhibition. These results highlight the pathogenic causative relevance of tDDR activation in IPF pathogenesis and support tASOs as a promising therapeutic strategy for IPF and for telomere biology diseases.

Open article ↗



2026-08-13 | Stepwise Translational Validation of the Screening Hit Desipramine Reveals Limits of Fibroblast-State Modulation in Lung Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited treatment options. Depression and anxiety are common comorbidities in patients with IPF, and emerging evidence suggests that neuroactive pathways may also influence fibrotic remodeling. On this basis, we investigated desipramine, a tricyclic antidepressant, as a potential modulator of fibroblast state in lung fibrosis. Desipramine was identified in an FDA-approved compound screen as a pro-lipogenic hit in TGF-β-stimulated fibroblasts and was subsequently evaluated across a stepwise validation pipeline of increasing biological complexity. In WI-38 fibroblasts, desipramine was well tolerated at 10 μM and reduced myofibroblast-associated features while increasing lipid-associated staining. In a fibroblast-supported alveolosphere assay, desipramine altered qualitative organoid clustering and changed the transcript levels of specific mesenchymal markers under profibrotic stimulation, whereas direct treatment of MLE-12 epithelial cells did not elicit a consistent response. While desipramine demonstrated pro-lipogenic and anti-myofibroblastic phenotypic shifts in reductionist 2D cultures, these effects failed to translate robustly into complex 3D human lung tissue slices or in vivo disease models. Ultimately, our findings highlight the critical necessity of utilizing complex translational pipelines to rigorously validate early screening hits before therapeutic efficacy is assumed.

Open article ↗



2026-08-13 | Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis.

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing interstitial lung disease characterized by excessive extracellular matrix (ECM) accumulation, disruption of lung architecture, and progressive loss of pulmonary function. IPF is frequently accompanied by comorbid conditions that exacerbate disease progression and negatively impact prognosis. To address the biological complexity of IPF, this study presents a comprehensive molecular systems architecture that enables a system-level understanding of biomolecular interactions within the fibrotic lung microenvironment in response to external and physiological triggers. Methods: A literature search is conducted using the Medical Subject Headings (MeSH) keywords in PubMed and MEDLINE to identify relevant peer-reviewed articles published from April 2008 to June 2025, with Google Scholar used solely to retrieve full-text versions of articles identified through this search. The systems biology tool CytoSolve® was used to perform the systematic review and to support the curation and development of the molecular systems architecture of IPF pathogenesis. Full-length articles that contained Medical Subject Headings keywords relevant to IPF pathogenesis were selected for a comprehensive review. A total of 150 studies published between April 2008 and June 2025 met the inclusion criteria and were included in the systematic analysis. This systematic review was not registered. Results: Findings were synthesized qualitatively into a multilayered molecular interactome rather than through statistical meta-analysis. The architecture integrates interactions across sixteen lung-associated cell types, including epithelial, endothelial, mesenchymal, immune, and stromal populations. Key external triggers-such as bleomycin (BLM), asbestos, silica, radiation, cigarette smoke, Herpes virus, and genetic mutations (SFTPC I73T), along with hypoxia associated with comorbidities-initiate coordinated cellular responses that converge on three fundamental pathological processes: inflammation, myofibroblast differentiation, and tissue remodeling. These interconnected processes collectively drive the initiation and progression of IPF. Conclusions: This molecular systems architecture unifies triggers, cellular components, molecular pathways, and biological processes into a multilayered framework for identifying therapeutic targets, biomarkers, and rational single- and combination-treatment strategies in IPF.

Open article ↗



2026-08-13 | Discovery of Pyrazole-Containing RGD Mimics with Anti-Fibrotic Efficacy in the Unilateral Ureteral Obstruction Mouse Model.

Fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), metabolic dysfunction-associated steatohepatitis (MASH), and kidney fibrosis represent a major unmet medical need. IPF patients have a mean survival of only 2-5 years, and despite this critical need, only two drugs have been approved in the past decade. These therapies offer limited efficacy and poor tolerability, underscoring the need for better options. Targeting αV integrins has emerged as a promising strategy, supported by strong preclinical data. While αVβ1/6 inhibitors are in clinical trials, our approach focused on developing pan-αV inhibitors with selectivity over αVβ8 and αIIbβ3 and oral pharmacokinetics. Through lead optimization, we identified compound 14, a potent inhibitor of αVβ1, αVβ3, αVβ5, and αVβ6, with high selectivity, oral bioavailability, and low IV clearance. In a mouse unilateral ureteral obstruction model, oral dosing of 14 (10 mg/kg/day for 8 days) reduced total collagen by 25% versus vehicle.

Open article ↗



2026-08-12 | Amprenavir Protects Lung Epithelial Cells From Pepsin Induced Inflammation and Fibrotic Changes.

Chronic reflux-related microaspiration is increasingly recognized as a modifiable risk factor for progressive fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic lung allograft dysfunction (CLAD). Nonacid reflux constituents, including the gastric enzyme pepsin, are thought to be a primary source of aspiration-attributed injury. We previously showed that the FDA-approved HIV protease inhibitor amprenavir reduces pepsin-mediated inflammation and fibrosis in in vivo and in vitro models of the upper airways. Repurposing amprenavir offers a novel strategy to prevent aspiration-related lung disease progression. Our aim was to evaluate time- and dose-dependent effects of pepsin on proinflammatory and fibrotic responses in human bronchial/tracheal epithelial cells (HBECs) and assess the protective role of amprenavir. HBECs were treated in triplicate with 0.1 or 1 mg/mL pepsin and/or 10 μM amprenavir at pH 6.5 for 15 or 30 min, followed by 6 or 24 h rest. Cell secretions were assessed by IL-8 and fibronectin ELISA, and cell lysate was assessed by E-cadherin, β-catenin, and vimentin Western blot. Low-dose pepsin exposure (15 min, 0.1 mg/mL, 6 h rest) induced IL-8 (p < 0.01), reversed by amprenavir (p < 0.01). High-dose pepsin (30 min, 1 mg/mL, 24 h rest) depleted E-cadherin (p < 0.05) and increased vimentin (p < 0.01), both reversed by amprenavir. Pepsin elicited dose- and time-dependent proinflammatory and fibrotic effects in airway epithelial cells in vitro, which were prevented by amprenavir. This supports the capacity of amprenavir to mitigate airway damage caused by chronic reflux-related microaspiration and highlights its potential therapeutic utility for progressive fibrotic lung diseases. N/A.

Open article ↗



2026-08-13 | The telomeric DNA damage response as a therapeutic target in idiopathic pulmonary fibrosis.

Telomere dysfunction and the telomeric DNA damage response (tDDR) activation correlate with aging and age-related diseases, including idiopathic pulmonary fibrosis (IPF). However, a causal role for tDDR in IPF pathogenesis has not been determined. IPF patients frequently bear germline mutations in telomerase genes, critically short telomeres, and markers of tDDR and cellular senescence. We previously demonstrated that telomeric antisense-oligonucleotides (tASOs) targeting telomeric non-coding RNAs are selective tDDR inhibitors. Here, we employed late-generation telomerase knockout mice as a genetic model of IPF. Systemic tASOs treatment reduces DDR-including in stem/progenitor cells-inflammation, and lung fibrosis in young, adult, and old mice. Markers of DDR correlate with lung pathology, and tDDR inhibition normalizes molecular and pathological phenotypes, uncoupling telomere lengths from their deleterious consequences. Transcriptomic changes in telomerase knockout mice recapitulate those observed in normal aged mice and in IPF patients, and they are reversed upon tDDR inhibition. These results highlight the pathogenic causative relevance of tDDR activation in IPF pathogenesis and support tASOs as a promising therapeutic strategy for IPF and for telomere biology diseases.

Open article ↗



2026-08-13 | Stepwise Translational Validation of the Screening Hit Desipramine Reveals Limits of Fibroblast-State Modulation in Lung Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited treatment options. Depression and anxiety are common comorbidities in patients with IPF, and emerging evidence suggests that neuroactive pathways may also influence fibrotic remodeling. On this basis, we investigated desipramine, a tricyclic antidepressant, as a potential modulator of fibroblast state in lung fibrosis. Desipramine was identified in an FDA-approved compound screen as a pro-lipogenic hit in TGF-β-stimulated fibroblasts and was subsequently evaluated across a stepwise validation pipeline of increasing biological complexity. In WI-38 fibroblasts, desipramine was well tolerated at 10 μM and reduced myofibroblast-associated features while increasing lipid-associated staining. In a fibroblast-supported alveolosphere assay, desipramine altered qualitative organoid clustering and changed the transcript levels of specific mesenchymal markers under profibrotic stimulation, whereas direct treatment of MLE-12 epithelial cells did not elicit a consistent response. While desipramine demonstrated pro-lipogenic and anti-myofibroblastic phenotypic shifts in reductionist 2D cultures, these effects failed to translate robustly into complex 3D human lung tissue slices or in vivo disease models. Ultimately, our findings highlight the critical necessity of utilizing complex translational pipelines to rigorously validate early screening hits before therapeutic efficacy is assumed.

Open article ↗



2026-08-13 | Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis.

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing interstitial lung disease characterized by excessive extracellular matrix (ECM) accumulation, disruption of lung architecture, and progressive loss of pulmonary function. IPF is frequently accompanied by comorbid conditions that exacerbate disease progression and negatively impact prognosis. To address the biological complexity of IPF, this study presents a comprehensive molecular systems architecture that enables a system-level understanding of biomolecular interactions within the fibrotic lung microenvironment in response to external and physiological triggers. Methods: A literature search is conducted using the Medical Subject Headings (MeSH) keywords in PubMed and MEDLINE to identify relevant peer-reviewed articles published from April 2008 to June 2025, with Google Scholar used solely to retrieve full-text versions of articles identified through this search. The systems biology tool CytoSolve® was used to perform the systematic review and to support the curation and development of the molecular systems architecture of IPF pathogenesis. Full-length articles that contained Medical Subject Headings keywords relevant to IPF pathogenesis were selected for a comprehensive review. A total of 150 studies published between April 2008 and June 2025 met the inclusion criteria and were included in the systematic analysis. This systematic review was not registered. Results: Findings were synthesized qualitatively into a multilayered molecular interactome rather than through statistical meta-analysis. The architecture integrates interactions across sixteen lung-associated cell types, including epithelial, endothelial, mesenchymal, immune, and stromal populations. Key external triggers-such as bleomycin (BLM), asbestos, silica, radiation, cigarette smoke, Herpes virus, and genetic mutations (SFTPC I73T), along with hypoxia associated with comorbidities-initiate coordinated cellular responses that converge on three fundamental pathological processes: inflammation, myofibroblast differentiation, and tissue remodeling. These interconnected processes collectively drive the initiation and progression of IPF. Conclusions: This molecular systems architecture unifies triggers, cellular components, molecular pathways, and biological processes into a multilayered framework for identifying therapeutic targets, biomarkers, and rational single- and combination-treatment strategies in IPF.

Open article ↗



2026-08-13 | Discovery of Pyrazole-Containing RGD Mimics with Anti-Fibrotic Efficacy in the Unilateral Ureteral Obstruction Mouse Model.

Fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), metabolic dysfunction-associated steatohepatitis (MASH), and kidney fibrosis represent a major unmet medical need. IPF patients have a mean survival of only 2-5 years, and despite this critical need, only two drugs have been approved in the past decade. These therapies offer limited efficacy and poor tolerability, underscoring the need for better options. Targeting αV integrins has emerged as a promising strategy, supported by strong preclinical data. While αVβ1/6 inhibitors are in clinical trials, our approach focused on developing pan-αV inhibitors with selectivity over αVβ8 and αIIbβ3 and oral pharmacokinetics. Through lead optimization, we identified compound 14, a potent inhibitor of αVβ1, αVβ3, αVβ5, and αVβ6, with high selectivity, oral bioavailability, and low IV clearance. In a mouse unilateral ureteral obstruction model, oral dosing of 14 (10 mg/kg/day for 8 days) reduced total collagen by 25% versus vehicle.

Open article ↗



2026-08-12 | Amprenavir Protects Lung Epithelial Cells From Pepsin Induced Inflammation and Fibrotic Changes.

Chronic reflux-related microaspiration is increasingly recognized as a modifiable risk factor for progressive fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic lung allograft dysfunction (CLAD). Nonacid reflux constituents, including the gastric enzyme pepsin, are thought to be a primary source of aspiration-attributed injury. We previously showed that the FDA-approved HIV protease inhibitor amprenavir reduces pepsin-mediated inflammation and fibrosis in in vivo and in vitro models of the upper airways. Repurposing amprenavir offers a novel strategy to prevent aspiration-related lung disease progression. Our aim was to evaluate time- and dose-dependent effects of pepsin on proinflammatory and fibrotic responses in human bronchial/tracheal epithelial cells (HBECs) and assess the protective role of amprenavir. HBECs were treated in triplicate with 0.1 or 1 mg/mL pepsin and/or 10 μM amprenavir at pH 6.5 for 15 or 30 min, followed by 6 or 24 h rest. Cell secretions were assessed by IL-8 and fibronectin ELISA, and cell lysate was assessed by E-cadherin, β-catenin, and vimentin Western blot. Low-dose pepsin exposure (15 min, 0.1 mg/mL, 6 h rest) induced IL-8 (p < 0.01), reversed by amprenavir (p < 0.01). High-dose pepsin (30 min, 1 mg/mL, 24 h rest) depleted E-cadherin (p < 0.05) and increased vimentin (p < 0.01), both reversed by amprenavir. Pepsin elicited dose- and time-dependent proinflammatory and fibrotic effects in airway epithelial cells in vitro, which were prevented by amprenavir. This supports the capacity of amprenavir to mitigate airway damage caused by chronic reflux-related microaspiration and highlights its potential therapeutic utility for progressive fibrotic lung diseases. N/A.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

143 orphan drug designations for Idiopathic pulmonary fibrosis, including 3 approved therapies.

143 orphan drug designations for Idiopathic pulmonary fibrosis, including 3 approved therapies.

Drug

Therapy type

Regulator

Orphan designation

Approval

Sponsor

4-(4-Bromo-2-oxo-3H-benzimidazol-1-yl)-N-(4-iodophenyl)piperidine-1-carboxamide

small molecules

EMA

2026-08-20

Oxcia AB

tazarotene

small molecules

FDA

2026-06-17

GRI Bio Operations, Inc.

tadalafil

small molecules

FDA

2026-03-23

Shenzhen Hanhui Pharmaceutical Technology Co., Ltd

small molecule inhibitor of ARG-1 and ARG-2

small molecules

FDA

2026-03-09

AstraZeneca Pharmaceuticals LP

tranilast lysate

small molecules

FDA

2026-03-09

Nuformix Technologies Limited

deupirfenidone

small molecules

FDA

2026-02-19

PureTech LYT 100, Inc., a subsidiary of PureTech Health plc

isoquinoline derivative containing diesters that inhibits BCL-xL

small molecules

FDA

2026-01-15

Nanjing Reju Therapeutics Co., Ltd.

Phe-Thr-Thr-Phe-Thr-Val-Thr

peptides

EMA

2026-01-09

Scendea (NL) B.V.

Deupirfenidone

small molecules

EMA

2026-01-09

Granzer Regulatory Consulting & Services GmbH

humanised monoclonal antibody-drug conjugate delivering an mTOR inhibitor payload

antibodies

FDA

2025-12-09

Bionevix Ltd

Adeno-associated virus vector serotype 6.2 containing human TERT gene

gene therapies

EMA

2025-12-09

Telomere Therapeutics S.L.

zampilimab

antibodies

FDA

2025-11-25

Chiesi Farmaceutici S.p.A.

Orvepitant maleate

small molecules

EMA

2025-11-21

Granzer Regulatory Consulting & Services GmbH

kynurenic acid

small molecules

FDA

2025-11-14

BirchBioMed Inc.

a humanized anti-S100A4 monoclonal antibody of immunoglobulin G4 isotype

antibodies

FDA

2025-10-24

Calluna Pharma AS

roflumilast

small molecules

FDA

2025-09-03

Transpire Bio Inc

Admilparant

small molecules

EMA

2025-08-22

Bristol-Myers Squibb Pharma EEIG

taladegib

small molecules

FDA

2025-06-18

Endeavor Biomedicines

Taladegib

small molecules

EMA

2025-05-22

Orphix Consulting GmbH

Tranilast

small molecules

EMA

2025-05-22

Boyd Consultants Limited

orvepitant

small molecules

FDA

2025-04-04

NeRRe Therapeutics Ltd

selective CXCR7 agonist

small molecules

FDA

2025-02-12

iLeadBMS Co., Ltd.

an autologous cell product derived from the human airway basal cells without any gene modification

cell therapies

FDA

2025-02-04

Regend Therapeutics Co., Ltd.

artesunate

small molecules

FDA

2024-11-18

Artasome Therapeutics, LLC

fluoro methyl gallocatechin gallate

small molecules

FDA

2024-07-18

Avanti Biosciences, Inc.

Humanized immunoglobulin G1 monoclonal antibody directed against WNT1-inducible signaling pathway protein-1

antibodies

FDA

2024-07-08

Mediar Therapeutics, Inc.

Nerandomilast

small molecules

EMA

2024-06-28

Boehringer Ingelheim International GmbH

Zinc (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate and (3S,9aS)-3-(1H-imidazol-5-ylmethyl)-octahydro-1H-pyrido[1,2-a]piperazine-1,4-dione

small molecules

FDA

2024-05-30

NovMetaPharma Co., Ltd.

lixudebart

antibodies

FDA

2024-05-24

Alentis Therapeutics AG

2-(Piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)benzoate

small molecules

FDA

2024-05-15

AgomAb Spain, S.L.

immunomodulatory inhibitor of high mobility group box 1

antibodies

FDA

2024-02-22

Spark Biopharma, Inc.

Bersiporocin

small molecules

EMA

2023-12-13

Propharma Group The Netherlands B.V.

Pyridine derivative containing pyridazine that inhibits lysophospholipase

small molecules

FDA

2023-11-08

Boehringer Ingelheim Pharmaceuticals, Inc.

zelasudil

small molecules

FDA

2023-08-14

Redx Pharma Plc

Human Umbilical Cord-derived Mesenchymal Stem Cell Injection

cell therapies

FDA

2023-08-09

Wuhan Optics Valley Vcanbiopharma Co., Ltd.

(R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl] amino}thiophen-2-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid

small molecules

FDA

2023-06-12

HiLung, Inc.

a humanized, immunoglobulin G subtype 4 anti-Amphiregulin monoclonal antibody

antibodies

FDA

2023-02-16

Pulmongene (Hong Kong) Co., Limited

imidazole derivative

small molecules

FDA

2023-02-01

InSilico Medicine Hong Kong Limited

Piperidine-containing autotaxin inhibitor

small molecules

FDA

2023-01-19

NextGen Bioscience

Ivaltinostat

small molecules

FDA

2023-01-03

Machaon Biotherapeutics, Inc.

(H-L-Arginyl-L-Valyl-L-Isoleucyl-L-Arginyl-L-Alanyl-L-Cysteinyl-L-Leucyl-Glycyl-L-Valyl-Glycyl-L-Leucyl-L-Leucyl-Glycyl-L-Asparaginyl-L-Leucyl-D-Alanyl-Glycyl-L-Lysyl-amino-PEG12-propionic acid)2 (Disulfide bond at Cys)

proteins

FDA

2022-12-13

CohBar, Inc.

(2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid

small molecules

EMA

2022-12-09

Pharma Gateway AB

ifenprodil

small molecules

FDA

2022-12-01

Algernon Pharmaceuticals Inc.

garadacimab

antibodies

FDA

2022-08-16

CSL Behring

Ex-vivo conditioned medium from cultured adult human mesenchymal stem cells

other

FDA

2022-08-15

Summa Bio-Solutions Inc.

nerandomilast [Jascayd]

small molecules

FDA

2022-08-15

2025-10-07

Boehringer Ingelheim Pharmaceuticals, Inc.

4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulfonamide

small molecules

FDA

2022-08-15

Modern Biosciences Ltd

Selective Colony Stimulating Factor-1 Receptor kinase inhibitor

antibodies

FDA

2022-07-27

Elixiron Immunotherapeutics Inc.

Pirfenidone

small molecules

EMA

2022-06-24

Regintel Limited

(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)-8-(quinolin-5-ylmethyl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide methane sulfonic acid

small molecules

FDA

2022-06-07

3Plus2 Pharma, LLC

Chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment

peptides

EMA

2022-05-16

JVM Europe B.V.

N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide

small molecules

FDA

2022-04-19

Tvardi Therapeutics, Inc.

Treprostinil sodium

small molecules

EMA

2022-03-16

Ferrer Internacional S.A.

((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)

small molecules

FDA

2022-03-08

APIE Therapeutics

glucagon-like peptide-1/glucagon/gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment

proteins

FDA

2021-05-10

Hanmi Pharmaceutical Co., Ltd.

axatilimab

antibodies

FDA

2021-04-07

Syndax Pharmaceuticals, Inc.

lithium carbonate

small molecules

FDA

2021-03-29

Lispiro LLC

Sodium-3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoate

small molecules

FDA

2021-02-23

Blade Therapeutics, Inc.

Fc-fusion protein comprised of an anti-CXCR4 i-body tethered at its C-terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1

proteins

FDA

2021-02-22

AdAlta Limited

N-(N-(4-(trifluoromethoxy)phenyl) carbamimidoyl)pyrrolidine-1-carboximidamide acetate (Or N1-(4-trifluoromethoxy)phenyl-N5-pyrrolidine biguanide acetate)

small molecules

FDA

2021-02-01

ImmunoMet Therapeutics Inc.

Treprostinil

small molecules

FDA

2020-12-07

United Therapeutics Corporation

Caveolin-1 Scaffolding Domain 7-Mer

peptides

FDA

2020-09-09

Lung Therapeutics, Inc.

Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-B-D-galactopyranosyl) sulfane

small molecules

FDA

2020-08-25

Galecto Biotech AB

Olitigaltin

small molecules

EMA

2020-08-21

Galecto Biotech AB

Sodium cromoglicate

small molecules

EMA

2020-06-26

IQVIA RDS Spain S.L.

Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-

small molecules

FDA

2020-05-18

Amplia Therapeutics

4-fluoro-5-((6-methylhexahydropyrrolo[3,4-b] pyrrol-5(1H)-yl) sulfonyl) isoquinoline

small molecules

FDA

2020-02-05

The National Institutes of Pharmaceutical R&D Co., Ltd

drug component, inhaled nitric oxide, of the inhaled nitric oxice/INOpulse® Device combination product

small molecules

FDA

2019-09-10

Mallinckrodt Pharmaceuticals Ireland Limited

(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol Hydrogen Chloride

small molecules

FDA

2019-08-05

Daewoong Pharmaceutical Co., Ltd.

N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide

small molecules

FDA

2019-07-22

Blade Therapeutics, Inc.

(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4,5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide

small molecules

FDA

2019-07-18

X-Rx, Inc.

(6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone

small molecules

FDA

2019-05-08

Beijing Tide Pharmaceutical Co., Ltd

cromolyn solution

small molecules

FDA

2019-04-11

Respivant Sciences, Inc.

saracatinib

small molecules

FDA

2019-03-11

AstraZeneca Pharmaceuticals, LP

5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine

small molecules

FDA

2019-02-25

Molecure S.A. (previously OncoArendi S.A.)

Autotaxin inhibitor

small molecules

FDA

2019-01-14

Bridge Biotherapeutics, Inc

small interfering RNA agent that targets human transforming growth factor-Eszett1 messenger RNA

RNAs

FDA

2018-12-19

Toray Industries, Inc.

15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester

small molecules

FDA

2018-12-17

Afimmune

(1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid

small molecules

FDA

2018-12-17

Bristol-Myers Squibb Company

5-(3,5-Dimethyl-4-hydroxybenzylamino)-3-(4-morpholin-4-yl-phenylamino)-1H-pyrazole-4-carboxylic acid amide

small molecules

FDA

2018-12-07

Metagone Biotech Inc.

Tilorone

small molecules

EMA

2018-08-24

Professor Marjukka Myllärniemi

(S)-(-)-3-(4-aminophenyl)-2-methoxypropanoic acid

small molecules

EMA

2018-08-24

Nogra Pharma Limited

small molecule inhibitor of integrins avb6 and avb1

small molecules

FDA

2018-08-01

Pliant Therapeutics, Inc.

soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide

small molecules

FDA

2018-07-09

Sunshine Lake Pharma Co., Ltd

small molecule selective inhibitor of c-Jun N-terminal kinase

small molecules

FDA

2018-06-27

Celgene Corporation

N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide

small molecules

FDA

2018-05-23

Arroyo Biosciences, LLC

6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride

small molecules

FDA

2018-04-04

Reviva Pharmaceuticals, Inc.

plasminogen (Human)

proteins

FDA

2017-12-14

Kedrion Biopharma Inc.

yinfenidone

small molecules

FDA

2017-08-10

Sunshine Lake Pharma Co., Ltd

2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile

small molecules

FDA

2017-06-08

Galapagos NV

small molecule inhibitor of the Wnt pathway

small molecules

FDA

2017-06-06

Biosplice Therapeutics, Inc.

nitric oxide

small molecules

FDA

2017-01-31

VERO Biotech

3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt

small molecules

FDA

2017-01-25

Vicore Pharma AB

human single domain antibody-like protein inhibitor of the chemokine receptor type 4

antibodies

FDA

2017-01-11

AdAlta Limited

Ziritaxestat [GLPG1690]

small molecules

EMA

2016-08-29

Lakefront Biotherapeutics

carbon monoxide

small molecules

FDA

2016-08-16

Proterris, Inc.

3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt

small molecules

EMA

2016-07-14

Vicore Pharma AB

monoclonal antibody targeting eotaxin-2

antibodies

FDA

2015-10-29

ChemomAb, Ltd.

Setogepram sodium [PBI-4050]

small molecules

EMA

2015-10-09

[INACTIVE] Prometic Pharma SMT B.V.

tetra-substituted porphyrin derivative containing manganese (III)

small molecules

FDA

2015-03-16

Aeolus Pharmaceuticals

lebrikizumab

antibodies

FDA

2015-03-09

Eli Lilly and Company

3-pentylbenzenacetic acid sodium salt

small molecules

FDA

2015-02-11

Liminal BioSciences Limited

1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid

small molecules

EMA

2014-11-19

Inventiva

tipelukast

small molecules

FDA

2014-10-20

MediciNova, Inc.

pirfenidone

small molecules

FDA

2014-07-31

Avalyn Pharma, Inc.

Humanised anti-alpha ν beta 6 monoclonal antibody

antibodies

EMA

2014-07-29

Biogen Netherlands B.V.

Nintedanib esylate [Ofev]

small molecules

EMA

2013-04-26

Boehringer Ingelheim International GmbH

Tralokinumab [CAT-354]

antibodies

EMA

2012-11-08

Medimmune Limited

tralokinumab

antibodies

FDA

2012-07-24

MedImmune Ltd.

Recombinant human pentraxin-2

proteins

EMA

2012-07-17

Roche Registration GmbH

pamrevlumab

antibodies

FDA

2012-07-06

FibroGen, Inc.

recombinant human Pentraxin-2; recombinant human Serum Amyloid P

proteins

FDA

2012-02-17

Genentech, Inc.

Tanzisertib [CC-930]

small molecules

EMA

2011-12-09

Celgene Europe Limited

4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol

small molecules

FDA

2011-09-23

Celgene Corporation

bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)

antibodies

FDA

2011-09-14

Sanofi US Services, Inc., A SANOFI COMPANY

nintedanib [OFEV]

small molecules

FDA

2011-06-29

2014-10-15

Boehringer Ingelheim Pharmaceuticals, Inc.

Recombinant humanized anti-LOXL2 monoclonal antibody

antibodies

FDA

2011-04-18

Gilead Sciences, Inc.

(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt

small molecules

FDA

2011-04-15

Bristol-Myers Squibb Company

Sar9, Met(O2)11-Substance P

proteins

FDA

2011-03-16

New Amsterdam Sciences

2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione

small molecules

EMA

2010-11-26

Calliditas Therapeutics AB

Ambrisentan [ABS-10-001]

small molecules

EMA

2010-10-01

Gilead Sciences International Limited

2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione

small molecules

FDA

2010-09-21

Calliditas Therapeutics AB

humanized monoclonal antibody against human integrin alphaVbeta6

antibodies

FDA

2010-08-05

Biogen Idec, Inc.

Cintredekin Besudotox

proteins

FDA

2010-04-30

Insys Development Company, Inc.

Macitentan [Opsumit]

small molecules

EMA

2010-01-28

Janssen Cilag International

ambrisentan

small molecules

FDA

2009-12-23

Gilead Sciences, Inc.

purified bovine type collagen

proteins

FDA

2009-04-27

Magnolia Therapeutics LLC

macitentan

small molecules

FDA

2009-04-14

Actelion Pharmaceuticals Ltd

bosentan

small molecules

FDA

2008-09-30

Actelion Pharmaceuticals Ltd

Bosentan monohydrate [Tracleer]

small molecules

EMA

2008-09-05

[INACTIVE] Actelion Registration Limited

ammonium tetrathiomolybdate

small molecules

FDA

2008-05-05

Pipex Pharmaceuticals, Inc.

Fresolimumab

antibodies

EMA

2008-04-01

[INACTIVE] Sanofi B.V.

carlumab

antibodies

FDA

2007-11-08

Janssen Biotech, Inc.

Interferon gamma

proteins

EMA

2007-10-29

mondoBIOTECH Laboratories AG

Interferon gamma

proteins

FDA

2007-10-11

mondoBIOTECH Laboratories AG

Interferon gamma-1B

proteins

EMA

2005-05-27

Intermune UK Limited

Acetylcysteine

small molecules

EMA

2005-01-26

Zambon Group S.p.A.

Pirfenidone [Esbriet]

small molecules

EMA

2004-11-16

Roche Registration GmbH

Heparin sodium [FibroCure]

other

EMA

2004-09-02

Werner Seeger

human anti-transforming growth factor-B1,2,3

antibodies

FDA

2004-07-09

Genzyme Corporation

pirfenidone [ESBRIET]

small molecules

FDA

2004-03-05

2014-10-15

Legacy Pharma Inc.

interferon gamma-1b

proteins

FDA

2002-09-12

InterMune, Inc.

Interferon beta-1a (recombinant human)

proteins

FDA

1999-01-07

Biogen Idec, Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.